Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Amazon’s move on Globalstar is not just another satellite headline. It is a deeper attempt to own spectrum, device-level connectivity, Apple continuity, and a bigger slice of the space economy at the same time. That has immediate implications for Globalstar, material strategic implications for Amazon, and a more complicated read-through for AST SpaceMobile.
Lonestar just expanded its StarVault relationship with Sidus, but the real question is not whether the story sounds exciting. The real question is whether Sidus can convert contracts, hosted payload wins and defense positioning into revenue before burn and dilution overwhelm the setup.
Plenty of companies announce an earnings date. Very few deserve a dedicated article just because of that. What makes this group worth watching is that each company is walking into its next business update with a specific pressure point that matters more than the quarter itself.
Fastly is no longer the same simple “broken CDN turnaround” story it looked like a couple of years ago. The April 2026 setup is more nuanced. The business is showing real improvement in mix and operating profile, 2025 revenue accelerated to 15% growth, free cash flow turned positive, non-GAAP operating income turned positive for the full year, and management guided to another year of revenue growth plus positive non-GAAP operating income in 2026. That is the hard foundation the market was missing for a long time.
A full bilingual EN/IT report for WordPress Custom HTML on Draganfly’s current setup, product stack, defense traction, financial reality, dilution profile, scenario map, and the catalysts that matter after the company’s early-2026 funding reset.
Teva entered 2026 with a more credible transformation story than it had just a few years ago. The company reported 2025 revenue of $17.3 billion, up 4% year over year, marking its third consecutive year of growth. That matters because Teva is still carrying the legacy of a global generics business, but the mix is gradually shifting toward innovative medicines, biosimilars, and pipeline assets that management believes can support more durable long-term growth.
Travere Therapeutics did not just clear another FDA box on April 13, 2026. It materially changed the shape of its equity story. FILSPARI, already commercial in IgA nephropathy, now has a second FDA-approved kidney disease indication: reduction of proteinuria in adults and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis, or FSGS, without nephrotic syndrome. That is a narrower label than the most aggressive bulls had once hoped for, but it is still a real commercial approval, not a consolation prize, and it makes FILSPARI the first and only FDA-approved medicine for FSGS.
Hoth added another mechanistic layer to its HT-VA obesity / fatty-liver narrative today, with gene-level data showing reduced Srebf1 and increased Pparα in a VA / Emory CRADA model. That strengthens the scientific story, but it does not remove the core market question: can HOTH turn early preclinical promise and encouraging HT-001 oncology-supportive data into a financed, executable development path without crushing dilution?
From edge-AI pitch to real program conversion: what today’s autonomous-energy-node order says about OSS, how the business changed after the Bressner divestiture, and what still has to go right before this can be treated as a durable public-market winner.
Momentus is still one of the most binary small-cap space stories on the board, but after the last two weeks it is harder to dismiss the company as a pure concept trade. The central reason is not a promotional headline. It is sequence. For a company like MNTS, sequence is everything.
Static Finviz chart at the top. Referral applies only if a reader clicks through. NASDAQ: ONDS Defense · Counter-UAS · ISR · Robotics Updated April 13, 2026 Ondas (ONDS) Deep Dive April 2026 From a narrow drone narrative to a…
Allogene Therapeutics has spent years trying to prove that allogeneic, off-the-shelf CAR-T can become something more than a clever scientific pitch. Today’s ALPHA3 interim futility analysis does not finish that argument, but it materially changes the tone of it.
Daraxonrasib just turned a long-building RAS story into a frontline market conversation. The key question is no longer whether Revolution Medicines has a serious pancreatic program. The question now is how large the platform can become, how quickly the company can convert today’s Phase 3 win into approvals, and how much upside still remains after a violent breakout.
Two biotech names, two very different clinical stories, one synchronized release window. IDEAYA and Spyre are both scheduled to report clinically meaningful updates on Monday, April 13, 2026 at 8:00 a.m. ET, creating an unusually clean side-by-side setup for traders watching biotech volatility, narrative rotation, and cross-flow behavior before the actual readouts hit.
AMC is showing genuine operating improvement, but the common stock is still a highly leveraged instrument sitting underneath a very heavy capital structure.
The tone around PLUG has improved because the company finally delivered concrete signs of stabilization: positive Q4 gross profit, lower cash burn, a clearer execution roadmap, a new CEO, a signed strategic asset sale, and a fresh commercial win in electrolyzers. The key question now is no longer just survival. It is whether improving liquidity can translate into sustainable industrial execution.
A long-form look at how USA Rare Earth is trying to build an integrated non-China rare earth chain across Texas, Oklahoma, the U.K. and France, why the story now matters far beyond mining, and where the real upside and real execution risk sit today.
OPTT is no longer just the old “wave energy” micro-cap many traders remember. The company is trying to reposition itself as a maritime domain awareness and autonomous ocean systems story, with PowerBuoys, WAM-V platforms, Merrows software, defense-adjacent deployments, and a growing pipeline. The opportunity is obvious. The problem is obvious too: the revenue line is still tiny, the cash burn remains heavy, and the balance sheet still leans on dilution and convertible financing.
TLX101-Px accepted by FDA; PDUFA goal date set for September 11, 2026
The clearest near-term regulatory focal point is now TLX101-Px, Telix’s brain cancer imaging candidate for recurrent or progressive glioma. Management has also kept a H1 2026 target for the TLX250-Px / Zircaix BLA resubmission after working through the post-CRL comparability package.
Cingulate is one of those micro-cap biotech stories where the entire equity case has compressed into a narrow window: one lead ADHD asset, one PDUFA date, a visible commercialization build-out, and a very real dilution overhang.